Dr Reddy's Laboratories and Purdue University sign an MOU for research
Dr Reddy's Laboratories has entered into a pact with Purdue university to strengthen research on various parameters, including drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering
Dr Reddy's Laboratories has set its focus on pharmaceuticals research, and the fact is reiterated with the company signing an MOU with the US-based Purdue University. The single fold objective of the partnership is to drive results in pharmaceutical processes and product development including, drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology.
According to a release sharing news on the development, The MoU will advance the "Purdue Moves" drug discovery initiative to translate basic research into life-changing treatments. Purdue University has proven expertise on the matter, and this development will only help them translate more discoveries through the delivery of a medicine or technology.
As reported by PTI
Suresh Garimella, Purdue executive vice-president for research and partnerships, and his counterpart Amit Biswas, executive vice-president and global head of integrated product development, signed the MoU last month.
Areas of planned collaborative research and education include targeted drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology.
"The collaboration will include student engagement and faculty exchanges and may include a site at Purdue Research Park," the statement further said.
Biswas said the long-term research partnership will help accelerate innovative drug development and manufacturing excellence.
"The long-term research partnership augurs well for DRL's philosophy of providing access to innovative, high-quality medicines to global patients at affordable cost," he added.
Dr Reddy's Laboratories has set its focus on pharmaceuticals research, and the fact is reiterated with the company signing an MOU with the US-based Purdue University. The single fold objective of the partnership is to drive results in pharmaceutical processes and product development including, drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology.
According to a release sharing news on the development, The MoU will advance the "Purdue Moves" drug discovery initiative to translate basic research into life-changing treatments. Purdue University has proven expertise on the matter, and this development will only help them translate more discoveries through the delivery of a medicine or technology.
As reported by PTI
Suresh Garimella, Purdue executive vice-president for research and partnerships, and his counterpart Amit Biswas, executive vice-president and global head of integrated product development, signed the MoU last month.
Areas of planned collaborative research and education include targeted drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology.
"The collaboration will include student engagement and faculty exchanges and may include a site at Purdue Research Park," the statement further said.
Biswas said the long-term research partnership will help accelerate innovative drug development and manufacturing excellence.
"The long-term research partnership augurs well for DRL's philosophy of providing access to innovative, high-quality medicines to global patients at affordable cost," he added.
Next Story
